Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteris Technologies (AVR) is working to secure a $20 million funding package to be used primarily on future research and development
  • The company has developed a piece of tech called DurAVR, which is a 3D single-piece aortic valve used in the treatment of aortic stenosis
  • This new funding package is made up of a $1 million placement and a potential $2.5 million convertible note fund from Mercer Street Global Opportunity Fund
  • The New York-based investment group may also provide $16.5 million via a put option agreement, dependent on AVR shareholder approval
  • Shares in AVR are trading up 7.47 per cent at $4.03 each

Anteris Technologies (AVR) has potentially secured $20 million in funding to be used primarily on future research and development.

The company has developed a piece of tech called DurAVR, which is a 3D single-piece aortic valve used in the treatment of aortic stenosis.

Funding deal

AVR has signed a deal with Mercer Street Global Opportunity Fund for a placement, convertible note and put option agreements.

The New York-based investment group will buy $1 million in AVR shares, with each share priced at $3.43.

Mercer will then buy $1.5 million in convertible notes from Anteris, with the option to buy an additional $1 million in notes if shareholders approve or if the company has existing capacity.

If all of the deals go through, the investment group may also provide $16.5 million in extra funding via a put option agreement.

The agreement is subject to AVR shareholder approval and would essentially mean Mercer is required to buy new Anteris shares in ongoing tranches.

Bolstered balance

All up, the initial placement to Mercer, as well as a private placement announced at the end of last month and a recent research and development advance, leaves Anteris with $4.8 million in new funds.

"We are excited to partner with Anteris through this crucial stage of its development and to add a promising MedTech player to our portfolio," Mercer Managing Member Jonathan Juchno said.

"We believe AVR's technology could drastically change the landscape of the aortic valve replacement market. We have the highest confidence in Anteris' management to unlock that potential through 2021," he added.

Shares in Anteris Technologies are trading up 7.47 per cent at $4.03 each at 12:44 pm AEDT.


AVR by the numbers
More From The Market Herald
Jayex Healthcare (ASX:JHL) - Executive Chairman, Michael Boyd - The Market Herald

" Jayex Healthcare (ASX:JHL) to divest hospital queue management business

Jayex Healthcare (JHL) has entered into an asset sale to divest its on-premises hospital queue management business.
Calix (CXL) - CEO, Phil Hodgson (left) - The Market Herald

" Calix (ASX:CXL) raises another $5M in oversubscribed SPP

Tech company Calix (CXL) has successfully raised $5 million through a heavily oversubscribed share purchase plan (SPP).
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences’ (ASX:RHY) clinician network joins ColoSTAT trial

Rhythm Biosciences (RHY) has confirmed its network of clinicians is the latest group to join the company’s clinical trial for ColoSTAT.
Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

" Shares in Island Pharmaceuticals (ASX:ILA) soar following ASX debut

Shares in antiviral drug developer Island Pharmaceuticals (ILA) have jumped almost 150 per cent following the completion of a $7.5 million IPO.